| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2021 | REGULONIX LLC | 1555 E ENTRADA SEGUNDA | TUCSON | AZ | 85718-5824 | PIMA | USA | R41CA257845 | Inhibition of CaV?-? interaction with orally available small organic molecules for chronic pain | 000 | 1 | NIH | 5/4/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2019 | REGULONIX LLC | 1555 E ENTRADA SEGUNDA | TUCSON | AZ | 85718-5824 | PIMA | USA | R41DA050364 | Optimization of Betulinic Acid analogs for T-type calcium channel inhibition for non-addictive relief of chronic pain | 000 | 1 | NIH | 10/22/2021 | $0 |
| | 2022 | 2019 | REGULONIX LLC | 1555 E ENTRADA SEGUNDA | TUCSON | AZ | 85718-5824 | PIMA | USA | R41NS116784 | Discovery of T-type Calcium Channel Antagonists from Multicomponent Reactions and Their Application in Paclitaxel-induced Peripheral Neuropathy | 000 | 1 | NIH | 11/28/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $819,470 ) |
| | 2021 | 2021 | REGULONIX, LLC | 1555 E ENTRADA SEGUNDA | TUCSON | AZ | 85718-5824 | PIMA | USA | R41NS122545 | Targeting the neuropilin-1 receptor (NRP-1)/VEGF-A axis for neuropathic pain | 000 | 1 | NIH | 8/30/2021 | $419,470 |
| | 2021 | 2021 | REGULONIX, LLC | 1555 E ENTRADA SEGUNDA | TUCSON | AZ | 85718-5824 | PIMA | USA | R41NS122545 | Targeting the neuropilin-1 receptor (NRP-1)/VEGF-A axis for neuropathic pain | 001 | 1 | NIH | 9/19/2021 | $0 |
| | 2021 | 2021 | REGULONIX, LLC | 1555 E ENTRADA SEGUNDA | TUCSON | AZ | 85718-5824 | PIMA | USA | R41CA257845 | Inhibition of CaV?-? interaction with orally available small organic molecules for chronic pain | 000 | 1 | NIH | 4/26/2021 | $400,000 |
| | 2021 | 2019 | REGULONIX, LLC | 1555 E ENTRADA SEGUNDA | TUCSON | AZ | 85718-5824 | PIMA | USA | R41NS116784 | Discovery of T-type Calcium Channel Antagonists from Multicomponent Reactions and Their Application in Paclitaxel-induced Peripheral Neuropathy | 000 | 1 | NIH | 12/4/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | REGULONIX, LLC | 1555 E ENTRADA SEGUNDA | TUCSON | AZ | 85718-5824 | PIMA | USA | R41DA050364 | Optimization of Betulinic Acid analogs for T-type calcium channel inhibition for non-addictive relief of chronic pain | 001 | 1 | NIH | 9/10/2020 | $0 |
| | 2020 | 2019 | REGULONIX, LLC | 1555 E ENTRADA SEGUNDA | TUCSON | AZ | 85718-5824 | PIMA | USA | R41NS116784 | Discovery of T-type Calcium Channel Antagonists from Multicomponent Reactions and Their Application in Paclitaxel-induced Peripheral Neuropathy | 000 | 1 | NIH | 3/6/2020 | $0 |
| | 2020 | 2019 | REGULONIX, LLC | 1555 E ENTRADA SEGUNDA | TUCSON | AZ | 85718-5824 | PIMA | USA | R41DA050364 | Optimization of Betulinic Acid analogs for T-type calcium channel inhibition for non-addictive relief of chronic pain | 000 | 1 | NIH | 11/20/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $566,223 ) |
| | 2019 | 2019 | REGULONIX, LLC | 1555 E ENTRADA SEGUNDA | TUCSON | AZ | 85718-5824 | PIMA | USA | R41DA050364 | Optimization of Betulinic Acid analogs for T-type calcium channel inhibition for non-addictive relief of chronic pain | 000 | 1 | NIH | 9/17/2019 | $224,696 |
| | 2019 | 2019 | REGULONIX, LLC | 1555 E ENTRADA SEGUNDA | TUCSON | AZ | 85718-5824 | PIMA | USA | R41NS116784 | Discovery of T-type Calcium Channel Antagonists from Multicomponent Reactions and Their Application in Paclitaxel-induced Peripheral Neuropathy | 000 | 1 | NIH | 9/17/2019 | $341,527 |
|
| Issue Date FY: 2018 ( Subtotal = $0 ) |
| | 2018 | 2017 | REGULONIX, LLC | 1555 E ENTRADA SEGUNDA | TUCSON | AZ | 85718-5824 | PIMA | USA | R41CA210857 | Regulators of NaV1.7 Channels: Novel Anti-Allodynic Drug Candidates | 000 | 1 | NIH | 8/6/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $299,999 ) |
| | 2017 | 2017 | REGULONIX, LLC | 1555 E ENTRADA SEGUNDA | TUCSON | AZ | 85718-5824 | PIMA | USA | R41CA210857 | Regulators of NaV1.7 Channels: Novel Anti-Allodynic Drug Candidates | 000 | 1 | NIH | 4/19/2017 | $299,999 |
|
|
